---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-255495"
form_type: "8-K"
ticker: "SLDB"
cik: "0001707502"
company_name: "Solid Biosciences Inc."
filed_at: "2022-09-30T23:59:59+00:00"
generated_at: "2026-06-23T06:24:52.439008+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Solid Biosciences to acquire AavantiBio; announces $75M private placement

## Summary
- Merger: Solid acquires AavantiBio through transitory subsidiary merger; AavantiBio survives as wholly owned.
- Private placement of 159,574,463 shares at $0.47/share for ~$75M from accredited investors.
- Closing requires stockholder approval; private placement closes immediately after merger.
- Combined pipeline includes SGT-003 for Duchenne, AVB-202 for Friedreich's ataxia, AVB-401 for BAG3.

## SEC filing metadata
- accession: 0001193125-22-255495
- form_type: 8-K
- ticker: SLDB
- cik: 0001707502
- company_name: Solid Biosciences Inc.
- filed_at: 2022-09-30T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1707502/000119312522255495/0001193125-22-255495-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1707502/000119312522255495/d391920d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-255495
- JSON: https://secwatch.observer/filing/0001193125-22-255495.json
- Plain text: https://secwatch.observer/filing/0001193125-22-255495.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.